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Background: The Mre11-Rad50-Nbs1 (MRN) complex is well known for its crucial role in initiating DNA double
strand breaks (DSBs) repair pathways to resistant irradiation (IR) injury and thus facilitating radioresistance which
severely reduces radiocurability of nasopharyngeal cancer (NPC). Targeting native cellular MRN function would
sensitize NPC cells to IR.
Methods: A recombinant adenovirus containing a mutant Rad50 gene (Ad-RAD50) expressing Rad50 zinc hook
domain but lacking the ATPase domain and the Mre11 interaction domain was constructed to disrupt native
cellular MRN functions. The effects of Ad-RAD50 on the MRN functions were assessed in NPC cells lines using
western blot, co-immunoprecipitation and confocal microscopy analyses. The increased radiosensitivity of transient
Ad-RAD50 to IR was examined in NPC cells, including MTT assay, colony formation. The molecular mechanisms of
radiosensitization were confirmed by neutral comet assay and western bolts. Nude mice subcutaneous injection,
tumor growth curve and TUNEL assay were used to evaluate tumor regression and apoptosis in vivo.
Results: Rad50 is remarkably upregulated in NPC cells after IR, implying the critical role of Rad50 in MRN functions. The
transient expression of this mutant Rad50 decreased the levels of native cellular Rad50, Mre11 and Nbs1, weakened the
interactions among these proteins, abrogated the G2/M arrest induced by DSBs and reduced the DNA repair ability in
NPC cells. A combination of IR and mutant RAD50 therapy produced significant tumor cytotoxicity in vitro, with a
corresponding increase in DNA damage, prevented proliferation and cell viability. Furthermore, Ad-RAD50 sensitized
NPC cells to IR by causing dramatic tumor regression and inducing apoptosis in vivo.
Conclusion: Our findings define a novel therapeutic approach to NPC radiosensitization via targeted native cellular
Rad50 disruption.
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The 5-year overall survival rate (OS) is at least 85.8 % for
the patients with early-stage NPC [3, 4] but less than 60 %
for advanced NPC after radiotherapy alone [5]. Improving
the radiotherapy dose alone would affect the anatomic
proximity of crucial structures and reduce the life quantity
[6]. NPC patients who exhibit radioresistance are a key
population that contributes to the observed poor out-
comes. Improving the sensitization of NPC to radiother-
apy represents a useful solution.is distributed under the terms of the Creative Commons Attribution 4.0
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(IR) is DNA double-strand breaks (DSBs), however,
tumor cells exhibit a high capacity to repair DNA
DSBs. Thus, the molecules or proteins responsible for
DNA repair following radiotherapy are emerging as
potential therapeutic targets for sensitizing cancer
cells to radiotherapy and protecting surrounding
normal tissues.
The Mre11-Rad50-Nbs1 complex (MRN complex) facil-
itates the following two DSBs repair pathways in humans:
homologous recombination repair (HR) and non-
homologous end joining (NHEJ). This complex plays cru-
cial roles, including the detection of DSBs and subsequent
signaling, such as the activation of ATM kinase (a key
DSBs signaling protein), cell cycle regulation and telomere
maintenance [7, 8]. The role of the MRN complex in
the response to DSBs as well as its requirement for
cellular survival makes it a potential target for sensi-
tizing cancer cells to therapy. Rhee et al. constructed
recombinant adenoviruses to disrupt Nbs1 function
and enhance the radiosensitivity of head and neck tumors
[9]. A previous study also found that the disruption of
Rad50 function enhanced the chemosensitivity of head
and neck cancer [10].
The human RAD50 (hRAD50) gene is located at
chromosome 5q31 and encodes the 153 kDa Rad50 pro-
tein. It is an ATP-modulated DNA crosslinker that con-
sists of the following three important domains: the
bipartite ATP-binding cassette (ABC) domain, the
Mre11 interaction site, and the zinc hook region. As a
key component of the Mre112/Rad502 heterotetramer,
hRAD50 is the essential for the formation of functional
MRN complex. The ABC domain of Rad50 exhibits both
the ATPase and adenylate kinase activity that are essen-
tial for all the known functions of the MRN complex
[11, 12]. ATP binding to the ABC domain induces a con-
formational switch of the Rad50 protein, increasing the
affinity for its substrate, promotes the Rad50-mediated
regulation of Mre11 exonuclease activity [13–15], and
allows the zinc hook region of Rad50 to form a protrud-
ing end to link another opposing Rad50 protein [16].
During DSBs repair, whether through NHEJ or HR,
Mre11 and Rad50 form functional Mre112/Rad502 hetero-
tetramers that bind to opposing DNA ends or to sister
chromatids and are linked to the other heterotetramers
via dimerization of the Rad50 hook domains to initial
DSBs repair [16].
Given the known crucial roles of Rad50, we sought
to use a recombinant adenovirus construct containing
a mutant Rad50 gene, which consists only of the zinc
hook region, to abrogate the formation of the
Mre112/Rad502 heterotetramer, impair DSBs repair
capacity, and disrupt MRN function and radiosensitize
NPCs.Methods
Cells culture
The CNE1 and 5–8 F human nasopharyngeal carcinoma
cell lines were cultured in RPMI 1640 media supple-
mented with 10 % fetal bovine serum and 1 % penicillin-
streptomycin at 37 °C in 5 % CO2. No ethics approval was
required for the use of human cell lines in this study.
Recombinant adenoviral infection and IR treatment
A recombinant adenovirus (Ad-RAD50) containing a
fragment of the RAD50 hook located at the hinge do-
main of the wild-type Rad50 gene which express 13 kDa
mutant Rad50 protein and green fluorescence report
gene GFP was constructed in a previous study [17]. Ad-
EGFP without a fragment of the RAD50 hook was used
as the empty control adenovirus (Invitrogen Trading
(shanghai) Co. Ltd.). Cells were infected with recombin-
ant Ad-RAD50 at a corresponding MOI 50, 25 for
CNE1 and 5–8 F for 4 h at 37 °C, followed by replace-
ment with fresh 1640 media. The infected cells present
green fluorescence and 13 kDa mutant Rad50 proteins
indicated the successfully infection. The MOI of empty
control adenovirus was 100.
For the cells treated with Ad-RAD50 infection com-
bined with IR, the cells were infected with Ad-RAD50
for 4 h, followed by replacement with fresh 1640 media
for 24 h, and then were treated with IR. The 4Gy IR was
applied in this study. The survival rate of the cells
treated with 4Gy IR exhibited a significant growth inhib-
ition relative to the control-treated cells after 6 days, as
indicated by MTT assay. The cells exhibited a survival
rate of 0.59. So, all treatments except for colony forma-
tion were used 4Gy as the dose of IR. All assessments
for cells treated with IR or Ad-RAD50 combining with
IR were conducted at 24 h after IR.
Western blot analysis
Total protein was extracted from cells with different
treatments using total Protein Extraction Kit (KGP2100).
After boiling in SDS sample buffer, the supernatant were
analyzed on 10 % SDS-PAGE gels followed by transfer to
0.45 μm PVDF membranes (Millipore, USA). Nonspe-
cific binding sites were blocked using 5 % nonfat dried
milk in 1 × TBST buffer (10 mM Tris–HCl buffer at
pH 7.5, 125 mM NaCl, and 0.1 % Tween-20). The mem-
branes were incubated with different primary antibodies
overnight at 4 °C, respectively (polyclonal rabbit anti-
human Mre11 (ab33125,Abcam, UK), polyclonal rabbit
anti-human Rad50 (ab89, Abcam, UK), polyclonal rabbit
anti-human Nbs1 (ab32074, Novus, USA), monoclonal
rabbit anti-human Cdc25C (phospho S216) antibody
(ab32051, Abcam, UK), polyclonal rabbit anti-human-
CDK1 (phospho Y15) antibody (ab47594, Abcam, UK)
and polyclonal rabbit anti-human GAPDH (10494-1-AP,
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clonal goat anti-rabbit (CW0103,CWBIO, China). For all
the Western blot experiments, the primary antibodies
were used at a concentration of 1:1,000 ~ 1:3,000, and
the secondary antibody was used at a concentration of
1:3,000. A pre-stained standard marker (Thermo, USA)
was used for the estimation of protein molecular weight.
The FluorChem M System (protein simple, Alpha Inno-
tech Corp.) was used to visualize the protein bands and
capture images of the gels. Image J software was used to
analyze and quantify the densitys of the Western blot
bands.
Coimmunoprecipitation
Coimmunoprecipitation and immunoblot experiments
were conducted to verify the binding interactions be-
tween mutant Rad50 and the MRN complex. CNE1 cells
were either untreated or infected with Ad-RAD50,
twenty-four hours after plating into 150 mm culture
dishes, followed by replacement with fresh 1640 media.
At 24 h after infection, a subset of cells from the un-
treated and Ad-RAD50 infected groups were subjected
to 4Gy IR. At 24 h after IR, the cells were washed with
cold 1 × PBS, scraped into cell lysis buffer for Western
and IP (Beyotime, China) for 5 s, and gently transferred
into centrifuge tubes and centrifuged at 1,2000 rpm for
5 min at 4 °C. Lysate preclearing was performed by roll-
ing with BioepitopeR protein A + G agarose (Santa Cruz,
USA) at 4 °C on a microcentrifuge tube roller apparatus
for 1 h, followed by centrifugation at 1,2000 rpm for
1 min at 4 °C. The supernatants were retrieved and
quantified using a BCA assay (KEYGEN, Biotech,
China). Next, the cleared lysates were incubated with
polyclonal rabbit anti-human Mre11 antibody (Abcam,
USA) at a final concentration of ~2 μg Ab per 500 μg
lysate, with added ZnCl2 to a final concentration of
100 μM and rotated overnight at 4 °C. Immune com-
plexes were then precipitated by rolling the lysates with
BioepitopeR protein A + G agarose (Santa Cruz, USA)
overnight. The samples were centrifuged at 12,000 rpm
for 1 min at 4 °C. Immunoprecipitates bound to the
beads were washed 3 times with cell lysis buffer and
were added 50 μL of 2× loading buffer. The supernatant
was used for immunoblot analysis as described above.
Confocal microscopy
CNE1 cells were plated at a concentration of 7 × 105
cells/plate in 35-mm glass bottom culture plates with
15-mm glass bottoms for confocal microscopy (NEST
Biotechnology Co., LTD., China) and allowed to adhere
overnight. Next, the cells were either untreated or
treated with Ad-RAD50, followed by replacement with
fresh 1640 media after infection for 4 h at 37 °C. Adeno-
viral transgene induction was confirmed by visualizingGFP expression by fluorescence microscopy at 12 h after
infection. At 24 h after infection, a subset of cells was
subjected to 4Gy IR. Each dish was configured as fol-
lows: control cells (dish 1, 5, 9, 13), 4Gy-treated cells
(dish 2, 6, 10, 14), Ad-RAD50–infected cells (dish 3, 7,
11, 15), and Ad-RAD50 with 4Gy-treated cells dish 4, 8,
12, 16). After treatments with Ad-RAD50 infection and/
or IR, dishes 1–4 were treated with mouse monoclonal
anti-human Rad50 (ab89, Abcam) and rabbit polyclonal
anti-human Mre11 (Abcam) primary antibodies. Donkey
anti–rabbit IgG Antibodies Alexa Fluor 546 and donkey
anti–mouse IgG Antibodies Alexa Fluor 488 (Invitrogen)
were used as second antibodies. Dishes 5–8 were treated
with mouse monoclonal anti-human Rad50 and rabbit
polyclonal anti-human Rad50 (zinc hook region)
(NB100-1487, Novus Biological, USA) primary anti-
bodies, followed by donkey anti–rabbit IgG Antibodies
Fluor 546 and donkey anti–mouse IgG Antibodies Fluor
647 secondary anti-bodies. Dishes 9–12 were not treated
with any antibodies and served as controls. Dishes 13–
16 were treated only with secondary antibodies. The cell
nuclei were visualized by confocal microscope at × 63
magnification. Images were captured; image pro plus
software 6.0 was used to analyze signal co-localization.
Neutral comet assay
The neutral comet assay was used to quantify DNA DSBs.
CNE1 and 5–8 F cells that were not treated and all cells
infected with empty virus served as controls. The other
treatment groups were 4Gy IR alone, Ad-RAD50 infection
alone, Ad-RAD50 with 4Gy IR and empty-Ad with 4Gy
IR. All cells were grown as a monolayer in 6-well tissue
culture plates and then infected with either Ad-RAD50 or
empty-Ad over a 4-h period at 37 °C, followed by replace-
ment with fresh 1640 media. A subset of the cells was sub-
jected to with 4Gy IR. The neutral comet assay was
performed at 0, 24 and 48 h after IR treatments, according
to the manufacturer’s protocols (Trevigen, USA). The
slides were viewed at × 40 magnifications using a micro-
scope. Images of 30 randomly selected cells per samples
group were acquired. Comet measurement and quantita-
tive analysis were performed using CASP software. The
median tail moments (MTM) were used to quantitate the
extent of DNA DSBs.
Cell growth and survival test
Three samples of 3 × 103 log phase cells were plated in
96-well cell culture plates. The cells were incubated with
Ad-RAD or empty-Ad (MOI 50, 25 for CNE1 and 5–8 F
respectively) for 4 h at 37 °C. The cells were then cul-
tured with fresh 1640 media for 24 h after viral infec-
tion. Next, a subset of the CNE1 and 5–8 F were
subjected to 4Gy IR. After treatments, cell growth over
6 days was assessed by MTT assay.
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CNE1 and 5–8 F cells were plated at a concentration of
5 × 104 in 60-mm tissue culture dishes and allowed to
adhere overnight. Cells were untreated or infected with
Ad-RAD50 or Ad-EGFP for 4 h at 37 °C, and then cul-
tured with fresh 1640 media. Adenoviral transgene in-
duction was confirmed by visualizing GFP expression
under fluorescence microscopy 12 h after infection. Cells
were transferred to 6-wells culture plates (corning) at
70, 70, 140, 350, 1050, 3150 cells per well and allowed to
adhere overnight, and then were treated with 0, 1, 2, 4,
6, 8Gy, respectively. After 10 days, the cells were fixed
with 4 % paraformaldehyde, stained with Giemsa stain
kit (DM0002, LEAGE, Beijing Leagene Biotechnology
Co., Ltd., China), and scored by counting colonies under
an inverted microscope, using the standard definition
that a colony consists of 50 or more cells. Graph pad
prism 5.0 was used to fit surviving fraction curve using
the equation: Y = 1 ‐ (1 ‐ exp(‐ k * x))N.Ad-RAD50 treatment of NPC xenografts
Thirty nude mice were randomized into six groups of
five mice each. The right dorsal flank of each mouse was
injected subcutaneously with 3 × 106 CNE1 cells. After
the establishment of palpable tumors, mouse body
weight and external tumor volume were determined
regularly. External tumor diameter was measured using
digital calipers, and tumor volume was calculated using
the formula A2 × B × 0.5, where A represents the smal-
lest diameter and B equals the largest diameter. Eight
days after tumor injection, the average tumor volume
was approximately 200 mm3. All the mice were anesthe-
tized with 0.1 ml 4 % chloral hydrate per 10 g via intra-
peritoneal injection and divided into 6 groups (Control,
Ad-EGFP infection, Ad-RAD50 infection, IR, IR com-
bined with Ad-EGFP infection, and IR combined with
Ad-RAD50 infection). These six intervention groups
were intratumoral PBS buffer (50 μL volume), intratu-
moral Ad-RAD50 (8 × 108 PFUs in 50 μL volume), intra-
tumoral Ad-EGFP (8 × 108 PFUs in 50 μL volume),
respectively. Twenty-four hour after intratumoral injec-
tion, mice of corresponding groups were anesthetized
and suffered 6Gy IR treatment. The internal tumor vol-
ume was measured regularly until the tumors of controls
reached nearly 2,000 mm3 at 14th day after treatments.
The animal use protocol has been reviewed and ap-
proved by the Animal Ethical and Welfare Committee
(AEWC). The Approved No. is IACUC-DB-15-0304.Quantification of apoptosis in NPC tumors
Tumors were harvested from mice after size measure-
ment. Harvested tumors were fixed in 10 % neutral for-
malin, embedded in paraffin, and sectioned into 5-μMthick samples. TUNEL apoptosis staining using TUNEL
APOPTOSIS DET KIT (Millipore, America) was per-
formed according to manufacturer’s instructions. After
staining, five tumor specimens were randomly selected
from each treatment group. Ten × 40 high-powered
fields from each specimen were randomly selected. Im-
ages were acquired using the imaging system described
above. The percentage of apoptosis cells in each high-
powered field was calculated.
Statistics
Statistical analysis was performed using SPSS16.0. The
two-tailed Student’s t test for independent samples was
used for the analysis of all the data. P < 0.05 were consid-
ered statistically significant.
Results
Wild-type Rad50 is upregulated in NPC cells following IR
To avoid the influence of mutations and elucidate the
contributions of IR induced DNA-damage, we confirmed
the expression of wild-type MRN complex proteins in
CNE1 and 5–8 F cells after IR. As shown in Fig. 1, after
treatment of the cells with 4Gy IR, the Rad50 protein
was upregulated in the two cell lines. The expression of
Rad50 peaked at 24 h after IR of CNE1 cells. The ex-
pression levels of Nbs1 did not exhibit significant
changes in CNE1 cells but were upregulated in 5–8 F
cells, respectively (P < 0.05 for both).
Expression of the mutant Rad50 disturbed the MRN
complex formation
We hypothesized that the targeting of Rad50 and the
disruption of its interaction with the other two MRN
complex proteins would reduce radioresistance. To test
this hypothesis, we used an adenoviral vector established
in our previous study to infect the NPC cells. The
adenoviral vector contains a gene sequence encoding a
fragment of the Rad50 zinc hook region (Ad-RAD50),
which completely lacks the regions that encodes the
ATPase regions and Mre11 interaction sites [17]. As
shown in Fig. 2, Adenoviral transgene induction in
CNE1 infected with Ad-RAD50 (MOI = 50) was con-
firmed by visualizing green report gene expression under
fluorescence microscopy 12 h after infection. The ex-
pression of the 13-kDa mutant Rad50 protein was de-
tected by western blot in CNE1 cells infected with Ad-
RAD50. This truncated form of Rad50 only possesses
the hook domain, with which endogenous wild-type
Rad50 protein engages in zinc-mediated dimerization,
forming a single Mre112/Rad502 heterotetramer bound
to mutant Rad50. Because this mutant Rad50 adenoviral
vector lacks the Mre11 interaction site, it would abro-
gate the assembly of a second, functional Mre112/
Rad502 heterotetramer on the opposing DNA strand or
Fig. 1 The expression of MRN complex components in NPC cells. a and c The western blot of MRN complex proteins in CNE1 and 5–8 F after IR,
respectively. b and d The expression analysis of western blot in CNE1 and 5–8 F after IR, respectively. Wild-type Rad50 was upregulated at 12 and 24 h
after 4Gy IR treatment in CNE1 cells and was upregulated at 24 hours after 4Gy IR treatment in 5–8 F cells. Wild-type Nbs1 was found to be
upregulated in 5–8 F cells (P < 0.05). * P < 0.05
Chang et al. BMC Cancer  (2016) 16:190 Page 5 of 12sister chromatid. Furthermore, the impairment of Mre11
and Rad50 interaction elicited a subsequent effect on
Nbs1. In this study, we performed a series of confocal
microscopy experiments to demonstrate these binding
interactions. Cells treated with Ad-RAD50 infection, and
Ad-RAD50 infection plus 4Gy IR exhibited co-
localization of the signals representing wild-type Rad50
(blue) and Mre11 (red), suggesting the interaction be-
tween these two proteins (Fig. 3-a, -b). The co-localization
of the signals representing mutant Rad50 (red) and wild-
type Rad50 (blue) confirmed the interaction between these
two proteins in the cells infected with Ad-RAD50 (Fig. 3-c
and -d). A series of coimmunoprecipitation experiments
was used to confirm our microscopy findings. The results
confirmed the binding interaction between Mre11 andFig. 2 Ad-RAD50 infection and the expression of mutant Rad50 in NPC cel
b The expression of mutant Rad50 protein in the Ad-RAD50 infected CNE1wild-type Rad50 proteins based on the coimmunoprecipi-
tation of the wild-type Rad50 protein using an anti-
human Mre11 antibody (Fig. 3-e) and anti-human Rad50
antibody (Fig. 3-f) in all four groups. The Ad-RAD50
treatment significantly decreased the interaction between
wild-type Rad50 and Mre11, Mre11 and Nbs1 (Fig. 3-e,
-f). We confirmed that the mutant Rad50 interacted with
wild-type Rad50, thus weakening the interaction between
wild-type Rad50 and Mre11 and abrogating MRN com-
plex formation.
Ad-RAD50 infection downregulated MRN complex proteins
Our data indicated that a second Mre112/Rad502 hetero-
tetramer could not form proximal to the mutant Rad50
protein. We performed further western blot analysis tols. a The successful infection of Ad-EGFP and Ad-RAD50 in CNE1 cells.
cell
Fig. 3 The binding interaction between Rad50 and Mre11/mutant Rad50. a and b are the confocal assays of Ad-RAD50 infected CNE1 cells, c and
d the confocal assays of Ad-RAD50-treated CNE1 cells after IR. In (a) and (c), the overlap of the signals corresponds to wild-type Rad50 (blue) and
Mre11 (red). In (b) and (d), the overlap of the signals corresponds to wild-type Rad50 (blue) and mutant Rad50 (red), which suggests a binding
interaction between these proteins. e and f The co-IP of wild-type Mre11 and Rad50 in CNE1 cells. The Ad-RAD50-treated cells demonstrated
significant inhibition of the interaction with wild-type Mre11 with Rad50 and Nbs1. Cells with Ad-EGFP treatments were used as controls
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induce a dominant-negative downregulation of the
MRN complex by sequestering the wild-type Mre112/
Rad502 heterotetramer. The infection of Ad-RAD50
induced a downregulation of the wild-type Rad50 pro-
tein in CNE1 cells and 5–8 F cells (Fig. 4). At 24 hFig. 4 Infection of Ad-Rad50 downregulated the MRN proteins in NPC cell
Ad-RAD50 combing with 4Gy IR after 24 h; c and d are the corresponding
Nbs1 proteins was observed in CNE1 cells or 5–8 F cells treated with Ad-RA
combing with IR or not (the mean optical density of the Western blot banafter infection with Ad-RAD50, the Mre11 and Nbs1
proteins were also significantly downregulated in cells
treated with Ad-RAD50 alone or combing with 4Gy
IR. These results confirmed our hypothesis that the
disruption of wild-type Rad50 function by the mutant
Rad50 adenoviral vector influences the expression ofs. a and b are the MRN complex proteins in CNE1 infection with
results in 5–8 F cells. Downregulation of wild-type Mre11, Rad50, and
D50 infection compared to uninfected and Ad-EGFP infected controls,
ds ± SEM is shown, * P < 0.05, ** P < 0.01)
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tributable for the reduction in the DSBs repair cap-
acity of the NPC cells.
Mutant Rad50 enhances the IR cytotoxicity and IR
sensitivity
We used a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) cell growth assay
to measure the growth of the CNE1 and 5–8 F NPC
cells. Each cell line was divided into the following six
groups: no treatment control, Ad-EGFP empty control
virus-treated, Ad-RAD50-treated, 4Gy IR-treated, Ad-
EGFP- and 4Gy IR-co-treated, and Ad-RAD50- and 4Gy
IR-treated. The adenoviral vectors were introduced at an
MOI of 50 for CNE1 and 25 for 5–8 F. Control-, Ad-
RAD50- and Ad-EGFP-treated cells exhibited relative
logarithmic growth. 4Gy IR reduced cell growth relative
to the controls of CNE1 and 5–8 F cells. Treatment withFig. 5 Ad-RAD50 enhanced the IR-induced cell growth suppression and IR
NPC cells treated with Ad-RAD50 and 4Gy IR combination exhibited signific
treatments. b and c Colony formation assay showed that Ad-RAD50 infectiAd-RAD50 plus 4Gy IR enhanced the reduction in the
growth of these NPC cells compared to IR alone. At day
6 of treatment, relative to the control, 4Gy IR alone and
Ad-RAD50 alone treatments, treatment with Ad-RAD50
and IR combination therapy produced 24.9, 19.8 and
27.9 % reductions in the density of the CNE1 cells, 81.0,
59.1 and 75.7 % decreases in the number of 5–8 F cells
(Fig. 5-a), respectively. Therefore, the expression of the
mutant Rad50 transgene potentiated the cytotoxic ef-
fects of radiation in NPC.
We further performed a colony formation assay to test
the effect of Ad-RAD50 combing with IR on NPC cells’
proliferation. As expected, Ad-RAD50 infection signifi-
cantly increased IR induced inhibition the capacities of
CNE1 and 5–8 F cells’ colony formation (as Fig. 5-b
shown). Relative to the IR alone, combination Ad-RAD50
with 4Gy, 6Gy, 8Gy IR produced corresponding 3.193 (SF
= 0.396 vs. 0.124), 5.949 (SF = 0.232 vs. 0.039) and 12.429sensitivity. a Cell growth suppression was measured by the MTT assay.
ant persistent proliferative suppression compared to all the other
on inhibited the cells survival fractions (* P < 0.05, ** P < 0.01)
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tion (SF) of the CNE1 cells (P < 0.01), and corresponding
2.300 (SF = 0.460 vs. 0.200), 7.919 (SF = 0.293 vs. 0.037)
and 9.190 (SF = 0.193 vs. 0.021) fold reductions in the sur-
vival fraction (SF) of the 5–8 F cells (P < 0.01) (Fig. 5-c).
Enhanced cytotoxicity is associated abrogated DNA DSBs
induced G2/M arrest and subsequently increased DNA DSBs
The key cytotoxic effect elicited by IR is DNA DSBs.
One of the mainly DSBs-induced responses is G2/M ar-
rest. Cdc25c phosphorylation and the downstream cdk1/
cyclinB kinase are pivotal in regulating G2/M transition.
In this study, Ad-RAD50 combined significantly de-
creased the phosphorylation of cdc25c and cdk1, which
directly contributed to the G2/M transition and thus re-
duced the DSBs repair times (Fig. 6-a). We hypothesized
that the infection of Ad-RAD50 would reduce the DSBs
repair capacity of the NPC cells, thereby resulting inFig. 6 Ad-RAD50 abrogated the DSBs-induced G2/M arrest and enhances I
decreased the p-cdc25c and p-cdk1-Y15 expression compared with IR alon
5–8 F cells detected by neutral comet assay at 24 h after IR, respectively. O
toward the anode, producing a comet tail. The mean olive tail movements
shown. Ad-RAD50 combined with 4Gy IR significantly increased DSBs compenhanced cytotoxicity in cells treated with combined
Ad-RAD50 infection and IR, and this reduced DSBs re-
pair capacity would be the result of the abrogation of
the G2/M arrest.
The CNE1and 5–8 F cells were assessed for DNA
DSBs using the neutral comet assay. In CNE1 cells, we
detected the MTM values for cells with Ad-EGFP, Ad-
RAD50 or not at 0, 24 and 48 h after 4Gy IR. We found
that the difference between different treatments was ob-
vious at 24 h after IR (Additional file 1: Figure S1). So,
the further analysis of the MTM values for 5–8 F cell
lines were evaluated among the different groups at 24 h
after IR. As shown in Fig. 6-b, in three cell lines, IR
alone increased the MTM values relative to the control
treatment (8.461 vs. 2.059, P = 7.2E-17, 6.217vs. 3.522, P
= 1.26E-9 in the CNE1 and 5–8 F cells). Ad-EGFP or
Ad-RAD50 alone resulted in weak increased MTM
values compared to the control treatment (6.705 andR-induced DNA damage. a Ad-RAD50 infection combining with IR
e or Ad-EGFP infection combining with IR. b DNA DSBs in CNE1 and
riginal magnification: ×40. Damaged and fragmented DNA migrates
(MTMs) measured by using CASP software. MTM values ± SEM are
ared to all the other groups (* P < 0.05, ** P < 0.01)
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8 F cells, P < 0.05). Ad-RAD50 combined with IR
made a huge increased MTM relative to IR alone
(38.086 vs. 8.461 in CNE1, P = 1.3E-17, 23.023 vs.
6.217 in 5–8 F cells, P = 3E-9).Fig. 7 Effect of Ad-RAD50 infection on radiosensitivity of NPC xenografts in
in each group when the mice were sacrificed 14 days after IR. b The tumo
combined with Ad-RAD50 could inhibit the tumor growth, in contrast to the
at the time of IR treatment on day 1 and animal sacrificed on day 14. d Mean
e The weights of tumors from xenografts on day 14 (Mean ± SEM). Ad-RAD50
compared with IR alone or IR combined with Ad-EGFP. f Tumor nodules were
Ad-RAD50 infection combined with IR significantly increased the number of a
Ad-EGFP. Scale bar: 50 μm; n = 3; Values are depicted as the Mean ± SEM; *P <Ad-RAD50 infection increased radiosensitivity in vivo
Control group tumors exhibited sustained growth fol-
lowing cancer cell injection (Fig. 7-a, -b, Additional file
2: Figure S2), between days 1 and 14, IR combined with
Ad-RAD50 infection significantly regressed the tumormice with IR treatment. a A photograph of a representative xenograft
r growth curve of CNE1 with different treatments. It was shown that IR
IR alone. c Mean internally measured tumor volume ± SEM immediately
internally measured change in tumor volume ± SEM in each group.
infection combined with IR significantly decreased tumor weight
subjected to TUNEL assays. g The quantitative analysis of TUNEL assay.
poptotic cells, when compared with IR alone or IR combined with
0.05 and **P < 0.01
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showed a 6.8 fold increase in tumor volume relative to
pretreatment size. By contrast, Ad-EGFP group tumors
showed 7.0 fold increases in tumor volume (P > 0.05)
and a single intratumoral injection of Ad-RAD50 in-
duced a significant suppression of tumor growth relative
to controls, with 5.23 fold increase in tumor volume
(P > 0.05, Fig. 7-c). Contrast to the IR alone (6.17 fold in-
crease) or combined with Ad-EGFP treatment (5.23 fold
increase), IR combined with Ad-RAD50 limited tumor
growth (the tumor only acquired 2.73 fold crease, P =
0.011). As Fig. 7-d shown, the volumes of tumors (the
mean volume change is 484.1 mm3) from mice treated
with Ad-RAD50 combined with IR obtained the lowest
growth when compared with the treatment IR alone (the
mean volume change is 1061.9 mm3, P = 0.015) or com-
bined with Ad-EGFP (the mean volume change is
969.9 mm3, P = 0.008). The mean weight (0.424 g) of tu-
mors from mice treated with Ad-RAD50 combined with
IR was decreased compared with mice treated with IR
alone (mean weight is 0.868 g, P = 0.046) or Ad-EGFP
combined with IR (mean weight is 0.754 g, P = 0.090)
(Fig. 7-e). There were no significant difference among
the weights of tumors from mice treated with Ad-
RAD50, Ad-EGFP, IR alone and control. Besides, there
was no significant difference in weight between treat-
ment groups and controls (Additional file 3: Figure S3).
No mice died during the experiment caused by treat-
ments. This suggests mutant RAD50 gene transfer, with
or without IR, is well tolerated.
TUNEL staining was used on tumor frozen sec-
tions, and the percentage of apoptotic cells was de-
termined (Fig. 7-f and -g). Nontreated controls had
low levels of apoptosis per high-powered field
(2.425 %), by contrast, IR induced significantly more
apoptosis, alone and combined with Ad-EGFP
(4.127 % and 4.227 %, respectively; P > 0.05 for both).
Combining Ad-RAD50 with IR markedly increased
the amount of apoptosis in mice (8.071 %) with re-
spect to either treatment with IR alone or combined
with Ad-EGFP (P < 0.001).
Discussion
Cancer cells can activate a series of pathways to repair
DSBs and to maintain proliferation, all of which might
significantly underlie radioresistance and tumor recur-
rence. It is apparent that an efficient DSBs repair re-
sponse may be a hallmark of radioresistance.
Previous studies investigating DNA damage-signaling
pathways have revealed that the MRN complex plays
central roles in DNA repair and cell cycle checkpoints,
and these molecules represent promising targets for
radiosensitization [18]. The treatment with Mre11
siRNA increases human tumor cells radiosensitivity. Theexpression of full-length Nbs1 protein markedly en-
hances the radiosensitivity of the HNSCC cell line
JHU011 [9, 19]. Besides, dysfunction of Rad50 directly
reduces MRN complex-mediated DNA repair [20]. It
was demonstrated that the phospho-site-specific
(S635G) Rad50 mutant abrogates its activating phos-
phorylation by ATM, and Rad50-deficient cells exhibited
defective DNA damage-induced signaling in cell cycle
control and DNA repair [21]. In current study, we found
that Rad50 was upregulated in irradiated NPC cells,
which confirmed that Rad50 was a crucial factor of
MRN complex function in NPC cells.
In order to enhance radiosensitivity by perturbing the
DSBs repair capacity of NPC cells, we used a recombin-
ant adenovirus containing a mutant Rad50 gene that
consists only of the zinc hook region. Our previous
study demonstrated that the infection of this recombin-
ant adenovirus would specifically impair the DNA repair
function of the MRN complex in head and neck tumor
cells [17]. In present study, co-confocal and coimmuno-
precipitation data confirmed that the mutant-Rad50
retained the ability to interact with the wild-type Rad50
via its zinc hook region but lost the ability to bind to
Mre11. As a result, functional Rad502/Mre112 heterote-
tramers could not be assembled proximal to this
mutant-Rad50, unlike wild-type Rad50, protein assembly
could not coordinate around the mutant RAD50 protein,
and a fully functional MRN octamer did not form.
Moreover, the disruption of wild-type Rad50 by infection
with the mutant-Rad50 repressed the levels of wild-type
Rad50, Mre11 and Nbs1. This would be induced by a
dominant-negative effect that disrupts the MRN com-
plex. This dominant-negative effect has also been previ-
ously demonstrated through the use of RNA
interference. Both transient and stable knockdown of the
wild-type Rad50 gene induced a concurrent suppression
in Mre11 and Nbs1 protein levels [22, 23].
The dysfunction of MRN would sensitize cells to
DNA-damaging agents [16, 21]. It was proved by our
comet assay results that NPC cells infected with Ad-
RAD50 exhibited defective DNA repair. Between the
NPC cells that were treated with or without IR, the mu-
tant Rad50-infected cells that were treated with IR ex-
hibited remarkable levels of DNA damage and the
highest MTM values. Failure of proper DSBs repair
would initial apoptosis, and MRN complex deficiency in-
duced apoptosis by activating ATM and the correspond-
ing downstream pathway [24, 25]. Besides, MRN related
DSBs repair responses also activate DSBs induced cell
cycle arrest. ATM activation induced by MRN complex
promotes cell-cycle checkpoint induction; subsequently
phosphorylate downstream cdc25c and cdk1/cyclinB
complex to induce G2/M arrest [26]. G2/M arrest abro-
gate would enhance the tumor cells sensitivity of IR. In
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in NPC through transcriptional activation of CHK1
(CHEK1) and CHK2 (CHEK2) checkpoint kinases
through direct binding to the CHK1 and CHK2 pro-
moters. Inhibition of MYC leads to the inactivation of
CHK1/CHK2 pathway, eliminates DSBs-induced G2/M
arrest, and subsequently promotes apoptosis and thus sen-
sitizes NPC cells to IR [27]. The CHK1 inhibitor, Go6976
enhances the radiosenstivity is also associated the G2/M
arrest abrogate [28]. In this study, we observed that Ad-
RAD50 infection decreased the phosphorylation of cdc25c
and cdk1. It was implied that the enhanced sensitivity of
NPC cells to IR via Ad-RAD50 infection is also associated
with abrogating DSBs induced G2/M arrest.
In addition to initialing DSBs repair, MRN complex
might be involved in the recruitment or activity of tel-
omerase or the maintenance of the telomeres, thus pre-
venting chromosome ends from being recognized as
DSBs [18]. Wild-type Rad50 was found to be a negative
regulator of telomere maintenance that downregulates
TRF1. Nbs1 downregulates TRF2 and contributes to
telomere maintenance [29, 30]. As a positive regulator of
telomere maintenance, the MRN complex induces TRF
phosphorylation by ATM, triggering the release of TRF1
from telomeres and promoting telomerase access to the
ends of telomeres [29]. Nbs1 was found to negatively
regulate telomere length, resulting in accelerated telo-
mere shortening in NBS cells [30]. Another mechanism
by which MRN regulates telomere length is the form of
recombination-mediated DNA replication known as al-
ternative lengthening of telomeres (ALT) [23]. Kavitha
et al. found that different cancer cells exhibit differential
expression of MRN components and that targeting
MRN complex subunits would affect the expression of
the other MRN subunits, thus sensitizing a subset of
cancer cells to radio- and/or chemotherapy [31]. In this
study, the expression of mutant Rad50 disrupted the
function of wild-type Rad50, abrogating proper MRN
complex function. Our data suggested that infection
with Ad-RAD50 increases the sensitivity of NPC cells to
IR, likely by shortening the length of their telomeres.
The same sensitization to IR has also been reported in
other cancers, such as head and neck cancer [9].
In all, Ad-RAD50 would enhance DSBs induced by IR,
abrogate G2/M arrest and thus reduce the DSBs repair
time, and probably impact maintenance of the telomeres
to prevent DSBs recognition via disturbing MRN com-
plex functions, Ad-RAD50 would increase the sensitivity
of NPC cells to IR. It was confirmed by that mutant
RAD50 expressed, MRN-deficient cells exhibited cell
growth inhibition by MTT assay in vitro, and by the col-
ony formation assay that Ad-RAD50 infection brought
out obviously decrease in NPC cells survival fraction
after IR. Moreover, Ad-RAD50 combined with IRproduced a dramatic tumor regression in human NPC
xenografts.
This is the first report to our knowledge translating a
RAD50-disrupting approach to antitumor therapy
in vitro and in NPC xenografts. Our findings represent a
novel strategy for increasing the radiosensitivity of NPC
in patients.
Conclusions
This study for the first time provides insight into a new
therapeutic approach to NPC radiosensitization via tar-
geted native cellular RAD50 disruption by expressing a
mutant rad50 only containing Rad50 zinc hook domain
but lacking the ATPase domain and the Mre11 inter-
action domain. This mutant rad50 expression would dis-
rupt native cellular MRN functions in abrogating DSBs
induced G2/M arrest, increasing DSBs induced by irradi-
ation and apoptosis, and finally sensitize NPC to IR
in vitro and in vivo.
Additional files
Additional file 1: Figure S1. Ad-RAD50 enhanced IR-induced DNA
damage in CNE1 cells at different times. (A), (B) and (C) show the DNA
DSBs in CNE1 tumor cells as detected by neutral comet assay at 0, 12
and 24 h after IR treatment, respectively. (D), (E) and (F) Damaged and
fragmented DNA migrate toward the anode, producing a comet tail.
Original magnification: ×40; the mean olive tail movements (MTMs),
which were measured in CNE1 at 0, 12 and 24 h, respectively, after IR
treatment using CASP software. MTM values ± SEM are shown. Ad-RAD50
combined with 4Gy IR significantly increased DSBs compared to all the
other groups (P < 0.001). * P < 0.05, ** P < 0.01. (TIF 3488 kb)
Additional file 2: Figure S2. NPC xenografts of mice with 6 different
treatments. (TIF 7044 kb)
Additional file 3: Figure S3. The final weights of mice with 6 different
treatments. (TIF 537 kb)
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